MIST Graph | Milestone Pharmaceuticals Inc.

MIST Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

2026-06-30: Revenue $559.00K; Cost of revenue $32.00K; Research and development $3.51M; Selling, general and administrative $22.65M.
2026-03-31: Revenue $238.00K; Cost of revenue $14.00K; Research and development $3.25M; Selling, general and administrative (m).
2025-12-31: Revenue (m); Cost of revenue (m); Research and development $5.52M*; Selling, general and administrative (m).
2025-09-30: Revenue (m); Cost of revenue (m); Research and development $3.94M; Selling, general and administrative (m).

Segment

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period end	Revenue	Cost of revenue	Research and development	Selling, general and administrative	Income tax	Net income
2026-06-30	$559.00K	$32.00K	$3.51M	$22.65M	(m)	-$28.61M
2026-03-31	$238.00K	$14.00K	$3.25M	(m)	(m)	-$26.07M
2025-12-31	(m)	(m)	$5.52M*	(m)	(m)	$45.59M*
2025-09-30	(m)	(m)	$3.94M	(m)	(m)	-$11.92M
2025-06-30	$0.00	$0.00	$3.67M	$8.86M	(m)	-$12.97M
2025-03-31	$0.00	$0.00	$4.98M	(m)	(m)	-$20.76M
2024-09-30	(m)	(m)	$3.96M	(m)	(m)	-$9.44M
2024-06-30	(m)	(m)	$2.81M	(m)	(m)	-$9.36M
2024-03-31	(m)	(m)	$3.64M	(m)	(m)	-$10.35M
2023-09-30	(m)	(m)	$6.72M	(m)	(m)	-$15.08M
2023-06-30	(m)	(m)	$8.62M	(m)	(m)	-$16.04M
2023-03-31	(m)	(m)	$10.26M	(m)	(m)	-$14.95M
2022-09-30	(m)	(m)	$9.83M	(m)	(m)	-$14.56M
2022-06-30	(m)	(m)	$10.66M	(m)	(m)	-$16.65M
2022-03-31	(m)	(m)	$8.77M	(m)	(m)	-$14.01M
2021-09-30	(m)	(m)	$9.73M	(m)	(m)	-$14.22M
2021-06-30	(m)	(m)	$9.43M	(m)	(m)	$770.00K
2021-03-31	(m)	(m)	$8.60M	(m)	(m)	-$12.51M
2020-09-30	(m)	(m)	$8.23M	(m)	-$17.00K	-$11.98M
2020-06-30	(m)	(m)	$8.62M	(m)	(m)	-$12.98M
2020-03-31	(m)	(m)	$11.87M	(m)	(m)	-$16.34M
2019-09-30	(m)	(m)	$9.54M	(m)	-$73.00K	-$12.83M
2019-06-30	(m)	(m)	$10.53M	(m)	-$4.00K	-$13.66M
2019-03-31	(m)	(m)	$7.76M	(m)	$22.00K	-$10.45M
2018-09-30	(m)	(m)	$3.91M	(m)	(m)	-$5.70M
2018-06-30	(m)	(m)	$2.55M	(m)	$2.00K	-$3.59M
2018-03-31	(m)	(m)	$3.09M	(m)	$16.00K	-$4.18M

Revenue and expense 6 month

Period end	Revenue	Cost of revenue	Research and development	Selling, general and administrative	Income tax	Net income
2026-06-30	$797.00K	$46.00K	$6.76M	$43.28M	(m)	-$54.68M
2025-06-30	$0.00	$0.00	$8.65M	$24.41M	(m)	-$33.73M
2024-06-30	(m)	(m)	$6.45M	(m)	(m)	-$19.72M
2023-06-30	(m)	(m)	$18.88M	(m)	(m)	-$30.99M
2022-06-30	(m)	(m)	$19.43M	(m)	(m)	-$30.66M
2021-06-30	(m)	(m)	$18.02M	(m)	(m)	-$11.74M
2020-06-30	(m)	(m)	$20.49M	(m)	(m)	-$29.32M
2019-06-30	(m)	(m)	$18.29M	(m)	$18.00K	-$24.11M
2018-06-30	(m)	(m)	$5.64M	(m)	$18.00K	-$7.77M

Revenue and expense 9 month

Period end	Research and development	Income tax	Net income
2025-09-30	$12.59M	(m)	-$45.65M
2024-09-30	$10.42M	(m)	-$29.16M
2023-09-30	$25.60M	(m)	-$46.07M
2022-09-30	$29.25M	(m)	-$45.21M
2021-09-30	$27.75M	(m)	-$25.97M
2020-09-30	$28.72M	-$17.00K	-$41.30M
2019-09-30	$27.84M	-$55.00K	-$36.94M
2018-09-30	$9.55M	$18.00K	-$13.47M

Revenue and expense 12 month

Period end	Research and development	Income tax	Net income
2025-12-31	$18.11M	(m)	-$63.06K
2024-12-31	$14.36M	(m)	-$41.52K
2023-12-31	$31.05M	(m)	-$59.69K
2022-12-31	$39.83M	(m)	-$58.39M
2021-12-31	$38.67M	(m)	-$42.85M
2020-12-31	$34.49M	-$17.00K	-$49.97M
2019-12-31	$41.98M	-$56.00K	-$55.23M
2018-12-31	$16.85M	$74.00K	-$23.18M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
CITIUS ONCOLOGY, INC. (CTOR)	United States	$0.097B	-1.49
Anixa Biosciences Inc (ANIX)	United States	$0.096B
ProMIS Neurosciences Inc. (PMN)		$0.102B
Acrivon Therapeutics, Inc. (ACRV)	United States	$0.091B	-1.03
Polaryx Therapeutics, Inc. (PLYX)	United States	$0.106B
Biomea Fusion, Inc. (BMEA)	United States	$0.107B	-3.30
Rallybio Corp (RLYB)	United States	$0.089B
Equillium, Inc. (EQ)	United States	$0.109B	-11.27
GENELUX Corp (GNLX)	United States	$0.110B	-3.83
ONCOLYTICS BIOTECH INC (ONCY)		$0.086B